Empowered Funds LLC Increases Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Empowered Funds LLC increased its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 5.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,809 shares of the company’s stock after purchasing an additional 2,278 shares during the quarter. Empowered Funds LLC owned approximately 0.08% of Voyager Therapeutics worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. ProShare Advisors LLC purchased a new position in shares of Voyager Therapeutics during the first quarter valued at approximately $101,000. Vanguard Group Inc. raised its holdings in Voyager Therapeutics by 27.8% in the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares in the last quarter. American International Group Inc. boosted its stake in shares of Voyager Therapeutics by 22.9% during the 1st quarter. American International Group Inc. now owns 19,397 shares of the company’s stock valued at $181,000 after purchasing an additional 3,610 shares in the last quarter. Lazard Asset Management LLC increased its position in shares of Voyager Therapeutics by 95.3% during the first quarter. Lazard Asset Management LLC now owns 18,742 shares of the company’s stock valued at $174,000 after buying an additional 9,146 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Voyager Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after buying an additional 37,144 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Trading Up 1.7 %

VYGR stock opened at $5.75 on Tuesday. The stock’s 50 day simple moving average is $6.54 and its 200 day simple moving average is $7.38. Voyager Therapeutics, Inc. has a 12-month low of $5.19 and a 12-month high of $11.72. The stock has a market capitalization of $314.12 million, a PE ratio of 8.10 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter in the prior year, the business earned ($0.59) EPS. On average, research analysts predict that Voyager Therapeutics, Inc. will post -1.03 earnings per share for the current year.

Insider Activity at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. This represents a 6.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 4.53% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on VYGR shares. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners assumed coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Wedbush dropped their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Finally, StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 18th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $17.00.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.